REG - Provexis PLC - Result of AGM

ProvexisAnnouncement

26/10/2023 14:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231026:nRSZ4423Ra&default-theme=true

RNS Number : 4423R  Provexis PLC  26 October 2023

26 October 2023

Provexis plc

('Provexis' or the 'Company')

 

Result of AGM

 

Provexis, the business that develops, licenses and sells the proprietary,
scientifically-proven Fruitflow® heart-health functional food ingredient,
announces that at the Company's Annual General Meeting, held earlier today,
all resolutions were duly passed. The proxy votes received from shareholders
on each resolution are set out below.

 

 Resolutions   Votes for    %       Votes against  %      Votes total  Votes withheld

               *                                          **           ***
 Resolution 1  218,457,528  99.92%  175,586        0.08%  218,633,114  158,510
 Resolution 2  218,254,507  99.93%  151,998        0.07%  218,406,505  385,119
 Resolution 3  218,343,020  99.97%  63,485         0.03%  218,406,505  385,119
 Resolution 4  217,532,174  99.59%  889,392        0.41%  218,421,566  370,058
 Resolution 5  217,891,434  99.69%  674,480        0.31%  218,565,914  225,710
 Resolution 6  217,692,013  99.60%  863,669        0.40%  218,555,682  235,942
 Resolution 7  218,304,493  99.90%  214,288        0.10%  218,518,781  272,843

 

 *    Includes discretionary votes
 **   Total votes cast do not include withheld votes
 ***  A vote withheld is not a vote in law and is not counted in the calculation of
      the proportion of votes 'For' or 'Against' any of the resolutions

 

For further information please contact:

 

 Provexis plc                                 Tel:         07490 391888

 Dawson Buck, Chairman                                        enquiries@provexis.com

 Ian Ford, CEO

 Allenby Capital Limited                      Tel:         020 3328 5656

 Nick Naylor / Liz Kirchner / Lauren Wright

 

 

Notes for editors

 

About Provexis plc

AIM quoted Provexis is focused on the development, licensing and sales of its
proprietary, scientifically-proven Fruitflow® heart-health functional food
ingredient.

 

Fruitflow is a natural, breakthrough ingredient that helps with platelet
aggregation. This helps promote normal blood flow and circulation, which in
turn benefits cardiovascular health. Fruitflow helps the platelets to
circulate freely and smoothly throughout your blood, without sticking to one
another or to the blood vessels themselves. Freely flowing blood helps reduce
stress on your cardiovascular system.

 

Fruitflow is a highly concentrated form of bioactives which is lycopene-free
and contains over 30 known anti-platelet compounds. Published clinical studies
have shown that Fruitflow works to maintain healthy blood flow in a similar
way to 75mg aspirin but with a milder and reversible action; Fruitflow has a
similar antiplatelet effect to a single dose of aspirin - but when taken
daily, it has none of aspirin's side effects.

 

The science behind Fruitflow has been validated by leading peer review
publications and regulatory authorities. Fruitflow is the only natural
antiplatelet to have a health claim approved by the European Food Safety
Authority, stating that 150mg of Fruitflow 'helps maintain normal platelet
aggregation, which contributes to healthy blood flow'.

 

Fruitflow has a number of specific health benefits which have been reflected
in separate patent filings for the use of Fruitflow in:

 

·    mitigating exercise-induced inflammation;

·    managing blood pressure;

·    protecting against the adverse effects of air pollution on the body's
cardiovascular system. Laboratory work has shown that Fruitflow can reduce the
platelet activation caused by airborne particulate matter, such as that from
diesel emissions, by approximately one third; and

·    conferring health benefits in modulating the gut microbiome of
humans, to include a reduction in TMAO, following the completion of a
successful human study which is further detailed here
www.dsm.com/human-nutrition/en/talking-nutrition/press-releases/2023-01-20-new-study-reveals-dsms-fruitflow-activates-gut-heart.html
(http://www.dsm.com/human-nutrition/en/talking-nutrition/press-releases/2023-01-20-new-study-reveals-dsms-fruitflow-activates-gut-heart.html)
.

 

Provexis sells a high quality dietary supplement product containing Fruitflow
and Omega-3 from its website www.fruitflowplus.com
(http://www.fruitflowplus.com) on a mail order basis. The product is also
available to purchase from Amazon.co.uk and from Holland & Barrett.

 

Provexis has been working with BYHEALTH for more than six years to support the
planned launch of a number of Fruitflow based products in the Chinese market.
Clinical studies conducted in China are typically required to obtain the
necessary regulatory clearances in China, and a significant investment in
eight separate Fruitflow studies has been undertaken at BYHEALTH's expense.
Completed studies have shown excellent results in use for Fruitflow, and they
provide strong evidence for the efficacy of Fruitflow on platelet function.

 

The Chinese regulatory system for functional health food ingredients, such as
Fruitflow, is governed by the State Administration for Market Regulation (the
'SAMR') and it is based on a defined list of permitted health function claims
which brand owners are permitted to use on product labels.

 

In August 2023 the Company was delighted to report that BYHEALTH had
submitted: i) the first application for a new permitted health function claim
and ii) some related product registration applications.

 

The significance of these major developments for Fruitflow in China is further
outlined here
www.nutraingredients-asia.com/Article/2023/09/05/china-set-to-approve-new-function-claims-for-health-foods#
(http://www.nutraingredients-asia.com/Article/2023/09/05/china-set-to-approve-new-function-claims-for-health-foods)
. BYHEALTH has noted that it has been working on the project since 2015, with
'tens of millions of funds' (RMB) invested by BYHEALTH in the research and
development work.

 

Provexis was founded in 1999 and is headquartered in Reading, Berkshire.
Provexis' shares are traded on the AIM market of the London Stock Exchange
under the ticker symbol PXS.

 

For further information, please visit www.provexis.com and
www.fruitflowplus.com (http://www.fruitflowplus.com) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGLQLFLXBLZFBD